bioMérieux Statistics

Total Valuation

bioMérieux has a market cap or net worth of GBP 11.22 billion. The enterprise value is 11.47 billion.

Market Cap	11.22B
Enterprise Value	11.47B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	Jun 7, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.20%
Shares Change (QoQ)	-0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	43.73M

Valuation Ratios

The trailing PE ratio is 32.17.

PE Ratio	32.17
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	5.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.16, with an EV/FCF ratio of 86.50.

EV / Earnings	32.89
EV / Sales	3.56
EV / EBITDA	15.16
EV / EBIT	23.12
EV / FCF	86.50

Financial Position

The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.14.

Current Ratio	2.21
Quick Ratio	1.20
Debt / Equity	0.14
Debt / EBITDA	0.62
Debt / FCF	3.57
Interest Coverage	162.92

Financial Efficiency

Return on equity (ROE) is 10.61% and return on invested capital (ROIC) is 8.55%.

Return on Equity (ROE)	10.61%
Return on Assets (ROA)	7.08%
Return on Capital (ROIC)	8.55%
Revenue Per Employee	235,633
Profits Per Employee	25,461
Employee Count	13,982
Asset Turnover	0.74
Inventory Turnover	1.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10.35% in the last 52 weeks. The beta is 0.22, so bioMérieux's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	+10.35%
50-Day Moving Average	102.23
200-Day Moving Average	100.32
Relative Strength Index (RSI)	69.61
Average Volume (20 Days)	35,736

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, bioMérieux had revenue of GBP 3.23 billion and earned 348.71 million in profits. Earnings per share was 2.94.

Revenue	3.23B
Gross Profit	1.80B
Operating Income	497.25M
Pretax Income	434.42M
Net Income	348.71M
EBITDA	732.09M
EBIT	497.25M
Earnings Per Share (EPS)	2.94

Full Income Statement

Balance Sheet

The company has 230.78 million in cash and 473.51 million in debt, giving a net cash position of -242.73 million.

Cash & Cash Equivalents	230.78M
Total Debt	473.51M
Net Cash	-242.73M
Net Cash Per Share	n/a
Equity (Book Value)	3.29B
Book Value Per Share	27.79
Working Capital	1.03B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 419.33 million and capital expenditures -286.73 million, giving a free cash flow of 132.60 million.

Operating Cash Flow	419.33M
Capital Expenditures	-286.73M
Free Cash Flow	132.60M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 55.72%, with operating and profit margins of 15.41% and 10.81%.

Gross Margin	55.72%
Operating Margin	15.41%
Pretax Margin	13.46%
Profit Margin	10.81%
EBITDA Margin	22.68%
EBIT Margin	15.41%
FCF Margin	4.11%

Dividends & Yields

bioMérieux does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-1.33%
Years of Dividend Growth	n/a
Payout Ratio	24.36%
Buyback Yield	-0.20%
Shareholder Yield	-0.20%
Earnings Yield	3.11%
FCF Yield	1.18%

Dividend Details

Stock Splits

The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.

Last Split Date	Sep 20, 2017
Split Type	Forward
Split Ratio	3

Scores

bioMérieux has an Altman Z-Score of 6.16.

Altman Z-Score	6.16
Piotroski F-Score	n/a